Bryan, Garnier & Co advises Mérieux Alliance for the divestiture of ShanH (the majority shareholder of the Indian vaccine company Shantha Biotechnics) to Sanofi-aventis

Bryan, Garnier & Co advises Mérieux Alliance for the divestiture of ShanH (the majority shareholder of the Indian vaccine company Shantha Biotechnics) to Sanofi-aventis

News published on September Thursday 17, 2009
Share on

Paris, September 17th 2009 - Bryan, Garnier & Co, the independent pan-European Investment bank focusing on growth companies, has advised Mérieux Alliance on the sale of ShanH, the majority shareholder of the Indian vaccine company Shantha Biotechnics (Shantha), to Sanofi-aventis, for a consideration of EUR550m.

Bryan, Garnier & Co acted as exclusive financial advisor to Mérieux Alliance, the family-owned Group dedicated to the fight against infectious diseases and cancer. 

Created in 1993, Shantha is a Biotechnology company based in Hyderabad, India. Shantha is a pioneer in the development and launching of high-quality vaccines at affordable prices.

Shantha develops, and manufactures vaccines through a state-of-the-art facility. Indeed, it launched in 1997 SHANVAC-B™, the first recombinant Hepatitis B vaccine produced in India, as well as a suite of innovative multivalent vaccines. In 2007, it launched SHAN5™, a pentavalent vaccine for the prevention of Diphtheria, Pertussis, Tetanus, Haemophilus influenza B and Hepatitis B which was successfully prequalified by the World Health Organization in 2008.

Shantha is a driving-force within the fast-growing and attractive vaccines segment, already addressing the needs of populations in Emerging countries. In addition, Shantha has established longstanding relationships with Supranational Agencies such as UNICEF and PAHO (Pan American Health Organization) to supply major international markets including Asia-Pacific, Africa and Latin America.

Under the terms of the agreement, Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, will support Shantha’s ongoing development as a platform to address the need for high quality affordable vaccination in international markets.

In successfully carrying out this divestiture, Bryan, Garnier & Co completed the largest worldwide vaccine transaction this year, representing the leading Healthcare transaction in France in 2009 to date. 

For more information, please contact:

Olivier Garnier | Managing Partner / +33 1 56 68 75 71 | ogarnier@bryangarnier.com

Virginie Lazès| Managing Partner – Head of Corporate Finance / +33 1 56 68 75 85 | vlazes@bryangarnier.com 

Jean-Yves Coste | Senior Advisor – Healthcare Corporate Finance / +33 1 56 68 75 68 | jycoste@bryangarnier.com 

Jacob Sayer | Director – Corporate Finance / +44 207 332 2552 | jsayer@bryangarnier.com 

Fabien Blondel | Analyst – Healthcare Corporate Finance / +33 1 56 68 75 38 | fblondel@bryangarnier.com

 

About Mérieux Alliance (www.merieux-alliance.com)

Drawing on a long tradition and renowned expertise in bioindustry, Mérieux Alliance, the family holding company of Alain Mérieux, is dedicated to constantly improving patient care worldwide by developing new biotechnology based solutions.

Mérieux Alliance comprises now four companies dedicated to public health that span the full range of healthcare: prevention, diagnosis, prognosis, treatment and clinical follow-up:
Under the leadership of Alain Mérieux, 10,000 people worldwide are part of Mérieux Alliance. The group achieved consolidated revenues of €1.3 billion in 2008.
Founded in 1993 by Dr. Varaprasad Reddy, Shantha, headquartered in Hyderabad, is one of the most innovative and dynamic private Biotech laboratory in India. It has established a commercial vaccine franchise in the developing world providing a high quality range of cost effective vaccines and a pipeline of mid to late stage product developments, covering most vaccine segments, from monovalent and multivalent pediatric and adult vaccines.

-          BioMérieux, based in Marcy l’Etoile (France), which is 59%-controlled. A worldwide group specialized in the field of in vitro diagnostics and industrial microbiological testing;
-          Silliker, based in Chicago (US), which is 89%-controlled. A network of food testing and consulting laboratories;
-          Transgene, based in Strasbourg (France), which is 55%-controlled. Dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases;
-          ABL Inc (Advanced BioScience Laboratories), based in Washington D.C. (US), which is 100%-owned. Specialized in virological research.

About Shantha Biotechnics (www.shanthabiotech.com)

About Bryan, Garnier & Co (www.bryangarnier.com)

Bryan, Garnier & Co is an independent investment bank specialising in European Healthcare, TMT and Renewable Energies growth companies. Bryan, Garnier & Co is positioned on three activities: Equity Research & Brokerage, Asset Management and Corporate Finance.

With more than 100 professionals Bryan, Garnier & Co has for over ten years offered the range of services and expertise of top-tier investment banks, yet has the level of attention to clients of a boutique outfit.

The Corporate Finance department of Bryan, Garnier & Co advises European privately or publicly-owned companies, entrepreneurs and financial investors in the following transactions:

-          Equity Capital Markets

-          Mergers & Acquisitions

-          Private Placements

Bryan, Garnier & Co is authorised and regulated by the Financial Services Authority (FSA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European Capital Markets.

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities